Kezar Life Sciences downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju downgraded Kezar Life Sciences to Neutral from Buy without a price target The company elected to announce the voluntary cessation of enrollment of new patients and dosing of ongoing patients in the Phase 2b PALIZADE trial of its lead candidate zetomipzomib, pending further evaluation, the analyst tells investors in a research note. The firm cites the current status of the PALIZADE program, and the uncertainty around the outlook for zetomipzomib, for the downgrade.